Literature DB >> 22307139

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Richard C Wu1, Shujuan Liu, Jessica A Chacon, Sheng Wu, Yufeng Li, Pariya Sukhumalchandra, James L Murray, Jeffrey J Molldrem, Patrick Hwu, Hanspeter Pircher, Gregory Lizée, Laszlo G Radvanyi.   

Abstract

PURPOSE: Tumor-specific T cells are frequently induced naturally in melanoma patients and infiltrate tumors. It is enigmatic why these patients fail to experience tumor regression. Given that CD8(+) T cells mediate antigen-specific killing of tumor cells, the focus of this study was to identify alterations in the differentiation of CD8(+) residing at the tumor site, with emphasis on a population expressing CD57, a marker for terminal differentiation. EXPERIMENTAL
DESIGN: We conducted flow cytometric analysis of CD8(+) tumor-infiltrating lymphocytes (TIL) isolated from 44 resected melanoma metastases with known T-cell differentiation markers. For comparison, peripheral blood mononuclear cells were isolated from matched melanoma patients. We sorted different CD8(+) subsets found in TIL and determined their effector functions. In addition, we carried out Vβ clonotype expression analysis of T-cell receptors to determine lineage relationship between the CD8(+) TIL subsets.
RESULTS: The majority of CD8(+) TIL was in the early-effector memory stage of differentiation. A significant population consisted of an oligoclonal subset of cells coexpressing CD27, CD28, CD57, and Granzyme B, with little or no perforin. These cells could be induced to proliferate, produce a high level of IFN-γ, and differentiate into CD27(-)CD57(+), perforin(high) mature CTL in vitro. Addition of TGF-β1 prevented further differentiation.
CONCLUSIONS: Our studies identified a novel subset of incompletely differentiated CD8(+) CTL coexpressing early effector memory and late CTL markers. This population resembles that found in patients with uncontrolled chronic viral infections. TGF-β1, frequently produced by melanoma tumors, may be a key cytokine inhibiting further maturation of this subset. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22307139      PMCID: PMC3343210          DOI: 10.1158/1078-0432.CCR-11-2034

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  The increase of IFN-gamma production through aging correlates with the expanded CD8(+high)CD28(-)CD57(+) subpopulation.

Authors:  E Bandrés; J Merino; B Vázquez; S Inogés; C Moreno; M L Subirá; A Sánchez-Ibarrola
Journal:  Clin Immunol       Date:  2000-09       Impact factor: 3.969

2.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Suchitra Pandey; Vanessa A York; Janice Arakawa-Hoyt; Hanspeter Pircher; Philip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

3.  Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.

Authors:  L Gorelik; R A Flavell
Journal:  Nat Med       Date:  2001-10       Impact factor: 53.440

4.  Recombinant human interleukins IL-1alpha, IL-1beta, IL-4, IL-6, and IL-7 show different and specific calcium-independent carbohydrate-binding properties.

Authors:  C Cebo; T Dambrouck; E Maes; C Laden; G Strecker; J C Michalski; J P Zanetta
Journal:  J Biol Chem       Date:  2000-10-24       Impact factor: 5.157

5.  Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.

Authors:  T Ohkawa; S Seki; H Dobashi; Y Koike; Y Habu; K Ami; H Hiraide; I Sekine
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

6.  Cutting edge: Virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection.

Authors:  Oliver Bannard; Matthew Kraman; Douglas T Fearon
Journal:  J Immunol       Date:  2010-11-10       Impact factor: 5.422

7.  Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Authors:  Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  Science       Date:  2002-09-19       Impact factor: 47.728

8.  Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma.

Authors:  Dainius Characiejus; Vita Pasukoniene; Nijole Kazlauskaite; Konstantinas P Valuckas; Tadas Petraitis; Mykolas Mauricas; Willem Den Otter
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

9.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

10.  Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection.

Authors:  Debbie van Baarle; Stefan Kostense; Egbert Hovenkamp; Graham Ogg; Nening Nanlohy; Margaret F C Callan; Nicole H T M Dukers; Andrew J McMichael; Marinus H J van Oers; Frank Miedema
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

View more
  10 in total

1.  Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer.

Authors:  Gisela María Suárez; Ana Laura Añé-Kourí; Amnely González; Patricia Lorenzo-Luaces; Elia Neninger; Eva Elena Salomón; Leamnet Cordero; Mauricio Catalá; Nuris Ledón; Karla Pereira; Malkon Guillermo Sánchez; Beatriz García; Tania Crombet; Zaima Mazorra; Danay Saavedra; Agustin Lage
Journal:  Cancer Immunol Immunother       Date:  2021-01-02       Impact factor: 6.968

2.  Immune signature of tumor infiltrating immune cells in renal cancer.

Authors:  Katharina Geissler; Paolo Fornara; Christine Lautenschläger; Hans-Jürgen Holzhausen; Barbara Seliger; Dagmar Riemann
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

3.  Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Authors:  A Pato; G Eisenberg; A Machlenkin; A Margalit; G Cafri; S Frankenburg; S Merims; T Peretz; M Lotem; G Gross
Journal:  Clin Exp Immunol       Date:  2015-08-28       Impact factor: 4.330

4.  PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.

Authors:  Marco Donia; Julie Westerlin Kjeldsen; Rikke Andersen; Marie Christine Wulff Westergaard; Valentina Bianchi; Mateusz Legut; Meriem Attaf; Barbara Szomolay; Sascha Ott; Garry Dolton; Rikke Lyngaa; Sine Reker Hadrup; Andrew K Sewell; Inge Marie Svane
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

5.  New insights on the role of CD8(+)CD57(+) T-cells in cancer.

Authors:  Richard C Wu; Patrick Hwu; Laszlo G Radvanyi
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

6.  Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.

Authors:  Xuekai Zhu; Shruthi Prasad; Simone Gaedicke; Michael Hettich; Elke Firat; Gabriele Niedermann
Journal:  Oncotarget       Date:  2015-01-01

7.  Rapid and efficient transfer of the T cell aging marker CD57 from glioblastoma stem cells to CAR T cells.

Authors:  Xuekai Zhu; Gabriele Niedermann
Journal:  Oncoscience       Date:  2015-05-15

Review 8.  Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.

Authors:  Yelei Guo; Kaichao Feng; Yao Wang; Weidong Han
Journal:  Protein Cell       Date:  2017-03-13       Impact factor: 14.870

9.  CD8+CD57+ T cells exhibit distinct features in human non-small cell lung cancer.

Authors:  Bing Huang; Rong Liu; Peiliang Wang; Zhiwei Yuan; Jianjian Yang; Hui Xiong; Ni Zhang; Qi Huang; Xiangning Fu; Wei Sun; Lequn Li
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

10.  PD-L1+CD8+ T cells enrichment in lung cancer exerted regulatory function and tumor-promoting tolerance.

Authors:  Yingxia Zheng; Li Han; Zheyi Chen; Yiyang Li; Bingqian Zhou; Rui Hu; Shiyu Chen; Haibo Xiao; Yanhui Ma; Guohua Xie; Junyao Yang; Xianting Ding; Lisong Shen
Journal:  iScience       Date:  2022-01-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.